ReachRxResearch
Home
Research
Sign Up
Low-Dose Oral Minoxidil Use for Pediatric Hair Disorders
Back to Research Hub
  1. Home
  2. Research Hub
  3. Low-Dose Oral Minoxidil Use for Pediatri…

Low-Dose Oral Minoxidil Use for Pediatric Hair Disorders

JAMA Dermatology·September 30
DermatologyPractice changingAlopeciaPediatric Hair DisordersScarring AlopeciaExpert Consensus / Delphi StudyVasodilatorChildPediatricMinoxidilSpironolactone

Summary

View source

What was studied

A modified Delphi consensus process (June 2025–March 2026) among 51 international experts to establish recommendations for low-dose oral minoxidil (LDOM) use in children aged <12 years with hair disorders, covering patient selection, dosing, safety, and monitoring.

Key findings

84 of 127 items reached ≥70% consensus: LDOM was supported for hair follicle miniaturization (100%), hair cycle abnormalities (100%), hair shaft disorders (84%), and adjunctive use in select scarring alopecia (98%) in children aged ≥4 to <12 years. Fixed dosing by weight (<20 kg: 0.250–0.625 mg; 20–40 kg: 1.250 mg; >40 kg: 1.875 mg) and weight-based dosing (0.01–0.02 mg/kg/d) both achieved consensus; escalation of 50–100% with reassessment every 3–6 months was endorsed. Routine baseline labs and BP monitoring were not deemed universally necessary in low-risk patients.

Study limitations

Full text was not accessible; findings derive from the abstract only. The process captured only clinicians treating >10 pediatric patients with LDOM, potentially biasing toward experienced adopters. Consensus does not substitute for controlled efficacy or safety trial data.

Clinical implications

Clinicians treating children aged ≥4 to <12 years with hair disorders can use LDOM as a structured, off-label option, selecting between fixed weight-based or mg/kg dosing and combining with agents like spironolactone or JAK inhibitors as the alopecia subtype warrants. Absolute contraindications are pericardial effusion/tamponade and pheochromocytoma; routine monitoring can be individualized by risk.

Caveats

  • Eligibility required treating >10 pediatric patients with LDOM, which may over-represent early adopters and under-represent hesitant or safety-cautious clinicians
  • Only the abstract was available for extraction; the full text may contain additional nuance on dosing, adverse events, and monitoring thresholds
  • The age floor of ≥4 years for LDOM use is consensus-derived and not validated by pharmacokinetic studies in young children
Show all 4
  • This is an expert consensus statement, not a controlled trial; recommendations reflect structured opinion from experienced clinicians rather than randomized efficacy or safety data

Related Questions

Explore related topics

What are the safety and efficacy data for oral minoxidil in children with alopecia areata?How does low-dose oral minoxidil compare to topical minoxidil for pediatric hair loss?What monitoring is recommended when starting oral minoxidil in pediatric patients?

Publication Details

Year
2026
Journal
JAMA Dermatology
Sample Size
n=49
Source
View article
Keep scrolling
More content below.
Up Next